Revenue
2022
2023
2024
2025
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | £672.8M | £668.8M | £689.7M | £593.4M |
| Research & development | — | £27.8M | £31.0M | £5.6M |
| Operating expenses | — | £147.7M | £143.5M | £96.5M |
| Operating income | £42.4M | £6.4M | £40.5M | £49.4M |
| Operating margin | 6.30% | 0.96% | 5.87% | 8.32% |
| Net income | £19.3M | £2.4M | £31.8M | £36.7M |
| Net profit margin | 2.87% | 0.36% | 4.61% | 6.18% |
| Basic EPSper basic share | £0.29 | £0.12 | £0.51 | £0.63 |
| Diluted EPSper diluted share | £0.29 | £0.12 | £0.51 | £0.62 |
Genus ($GNS-LSE) announced a £60 million share-buyback program after adjusted pre-tax profit rose 35% to £100.2 million. Revenue declined 2% to £658.1 million, but stronger profitability in its pig-genetics business and improvements in its ...